Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LM-2417 + toripalimab + tirelizumab
- Development stage
- Unknown
- Lead developer
- LaNova Medicines
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
LM-2417 + toripalimab + tirelizumab is an investigational combination regimen for advanced solid tumors. **LM-2417** is a bispecific antibody that functions as a sodium-dependent phosphate transport protein 2B (NaPi-2b) inhibitor, targeting phosphate metabolism in cancer cells. **Toripalimab** and **tirelizumab** are monoclonal antibodies against programmed death-1 (PD-1), acting as immune checkpoint inhibitors to enhance T-cell mediated antitumor immunity. This combination is being evaluated in clinical trials for its safety, tolerability, and antitumor activity in patients with advanced malignant solid neoplasms[1][3][5].
- Other names
- LM2417LM-2417LM 2417
02
Targets
SLC34A2 (Sodium-dependent phosphate transporter type IIb)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on LM-2417 + toripalimab + tirelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LM-2417 + toripalimab + tirelizumab.